Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Isis and Alnylam in RNAi deal

Executive Summary

In a product swap agreement involving double-stranded RNAi patents, Isis Pharmaceuticals licensed Alnylam Pharmaceuticals (therapeutics based on RNAi) rights to its patent estate relating to antisense mechanisms and oligonucleotide chemistry. In turn, Alnylam provided Isis with rights to its patent applications. The companies plan to develop and commercialize RNAi therapeutics.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Intra-Biotech Deal
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies